Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 1/20 | 0.54 |
| ▸ | PDK2 | Q15119 | 5/20 | 0.44 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.36 |
| ▸ | GSK3A | P49840 | 1/20 | 0.33 |
| ▸ | GSK3B | P49841 | 1/20 | 0.33 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | LIPG | Q9Y5X9 | 2/20 | 0.32 |
| ▸ | LPL | P06858 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | F11 | P03951 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL253500 | 0.86 | FFAR1 (0.57) | FFAR1PDK2DGAT1GSK3AGSK3B | |
| SCHEMBL2483324 | 0.85 | FFAR1 (0.58) | FFAR1PDK2DGAT1GSK3AGSK3B | |
| SCHEMBL2993758 | 0.84 | FFAR1 (0.57) | FFAR1PDK2DGAT1GSK3AGSK3B | |
| SCHEMBL15298112 | 0.82 | FFAR1 (0.52) | FFAR1DGAT1GSK3AGSK3BUCHL1 | |
| SCHEMBL17785673 | 0.82 | FFAR1 (0.54) | FFAR1PDK2DGAT1GSK3AGSK3B | |
| SCHEMBL3674968 | 0.82 | FFAR1 (0.54) | FFAR1PDK2DGAT1GSK3AGSK3B | |
| SCHEMBL1872577 | 0.79 | FFAR1 (0.57) | FFAR1PDK2LIPGLPL | |
| SCHEMBL1853942 | 0.79 | FFAR1 (0.57) | FFAR1PDK2LIPGLPL | |
| SCHEMBL29236822 | 0.79 | FFAR1 (0.54) | FFAR1PDK2L3MBTL1LIPGSMN1; SMN2 | |
| SCHEMBL20759 | 0.79 | FFAR1 (0.64) | FFAR1PDK2DGAT1LIPGLPL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4737443-A1 | SALT-INDUCIBLE KINASE INHIBITORY COMPOUND AND PHARMACEUTICAL COMPOSITION CONTAINING SAME | Tanabe Pharma Corporation (JP) | 2026-05-06 | — | — | EP | disclosed |
| US-20260062387-A1 | SALT-INDUCIBLE KINASE INHIBITOR COMPOUND AND PHARMACEUTICAL COMPOSITION INCLUDING THE SAME | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2026-03-05 | — | — | US | disclosed |
| WO-2024242169-A1 | SALT-INDUCIBLE KINASE INHIBITORY COMPOUND AND PHARMACEUTICAL COMPOSITION CONTAINING SAME | 田辺三菱製薬株式会社 | 2024-11-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260062387-A1 | SALT-INDUCIBLE KINASE INHIBITOR COMPOUND AND PHARMACEUTICAL COMPOSITION INCLUDING THE SAME | SIK1, SIK3, SIK2 | FFAR1 2539/4885PDK2 606/4885DGAT1 2055/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.